ENTO Rasio cepet Entero Therapeutics Inc.

Entero Therapeutics, Inc. (ENTO) develops advanced therapies for celiac disease and digestive pathologies. Current sales of gastroenterological drugs support cash flow, while asset consolidation costs are already priced in. Market share price fluctuations demonstrate a coefficient of 2.72, however, the business faces threats due to early-stage development, potential test failures, and a lack of full commercial profit amid a capital deficit.

Entero Therapeutics, Inc. (ENTO) operates in a pre-revenue stage, relying critically on external investments for drug development. The dynamics of the company's quick liquidity reflect its ability to cover short-term obligations without liquidating inventory. This metric aggregates cash and accounts receivable, excluding illiquid assets to assess the most stringent solvency scenario. While high values confirm a capital cushion, an excess of non-working funds may signal low resource efficiency.